Bartomeu Massuti

Medical Oncologist. This account should be temporary waiting until X restores my original @bmassutis account that has been hacked

[Valor Mental 🧠 @valormental]

La ansiedad desaparece cuando dejas de aferrarte a lo que no controlas y empiezas a querer que las cosas sean como son.

Usa los correos de https://t.co/bZf27fwBTv para poner en orden tu vida (hábitos, productividad, finanzas...) entendiendo qué te frena y cómo corregirlo.

[Bartomeu Massuti @bmassuti2]

https://t.co/okm7njHHch

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

🇪🇺 Yesterday, the European Commission approved lurbinectedin and tarlatamab for the treatment of patients with SCLC. This marks a major milestone for patients across Europe, providing access to the first two drugs in decades to demonstrate a survival benefit in this setting after years of setbacks and dozens of negative phase III trials in a particularly challenging disease. Kudos to everyone who helped make this happen.

https://t.co/GZAdez2d5p

[OncoAlert @OncoAlert]

Dear Colleagues at #ASCO26 🇺🇸
A Great way to start the Final day of the meeting, our sincere thanks to @ASCO faculty and staff for a magnificent meeting!!
3⃣5⃣3⃣Million Impressions
1⃣9⃣.3⃣K Posts
1⃣.4⃣K Participants

Thanking our Colleagues worldwide for their support!
WE ARE ALL @OncoAlert 🚨
As Always. For Colleagues.....By Colleagues

@DrChoueiri @urotoday @GlopesMd @montypal @OncBrothers @tompowles1 @neerajaiims @PGrivasMDPhD @brian_rini @nataliagandur @crisbergerot @NEJM @OncoReporte @CParkMD @realbowtiedoc @MoffittNews @StephenVLiu @zklaassen_md @RenoHemonc @DrYukselUrun @AmandaBinDC

[OncoAlert @OncoAlert]

RASolute 302 : Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

https://t.co/o2BtMfTRph

In this phase 3 trial of 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma, the oral RAS(ON) inhibitor daraxonrasib significantly improved outcomes versus investigator’s-choice chemotherapy🧪 . Median overall survival doubled (13.2 vs. 6.6–6.7 months), while progression-free survival also improved 📈 substantially (7.2–7.3 vs. 3.5–3.6 months). Benefits were consistent across populations, including RAS G12-mutant disease. Daraxonrasib demonstrated a manageable safety profile, with fewer treatment discontinuations than chemotherapy. #PancreaticCancer

@EileenMOReilly
@WainbergZev
@DrHendifar
@MiteshBorad
@FilippoPietran4
@DrShubhamPant
@ChiaraCrem1
@DrGManji
@md_oberstein
@GarridoLagunaMD

@pashtoonkasi @CathyEngMD @marklewismd @manjuggm @ARosen380 @KoheiShitara @GillSharlene @BenWestphalen @graokane

[OncoAlert @OncoAlert]

The #OncoAlertTopTweet 🚨Day Three #ASCO26
Post by @OncoAlert AF @GIMedOnc 🇺🇸

RASolute 302 with a concomitant NEJM pub
Oral RAS(ON) inhibitor daraxonrasib significantly improved outcomes compared with investigator’s choice

Ping: OncoAlert ❤️Pulse
@DrChoueiri 🇺🇸 @hoperugo 🇺🇸 @matteolambe 🇮🇹 @TiansterZhang 🇺🇸 @CathyEngMD 🇺🇸 @stolaney1 🇺🇸 @montypal 🇺🇸 @tompowles1 🇬🇧 @brian_rini 🇺🇸 @cdanicas 🇪🇸 @NiuSanford 🇺🇸 @amerseburger 🇩🇪 @GlopesMd 🇺🇸 @Icro_Meattini 🇮🇹 @PGrivasMDPhD 🇺🇸 @DrYukselUrun 🇹🇷 @nataliagandur 🇦🇷 @ElisaAgostinett 🇧🇪 @HHorinouchi 🇯🇵 @realbowtiedoc 🇺🇸 @to_be_elizabeth 🇮🇹 @UOzkerim 🇹🇷 @p_ciracimd 🇮🇹 @DrVilmaPBarcia 🇪🇸 @DraMartinezLago 🇪🇸 @DrMirallas 🇺🇸 @GaiaGriguolo 🇮🇹 @MarioBalsaMD 🇪🇸 @scocmem 🇬🇧 @AmandaNizamMD 🇺🇸 & @weoncologists 🇺🇸

[Nicholas Hornstein @GIMedOnc]

#ASCO26

This one is special.

This is the hottest paper of 2026 and potentially in the history of pancreatic cancer.

Let’s dive in.

RASolute 302: Daraxonrasib vs investigator’s choice chemotherapy in previously treated metastatic pancreatic cancer
Abstract LBA5 (soon!)
Presentation: May 31, 2026, 3:21-3:33 PM CDT

For decades, pancreatic cancer has been where good ideas go to die.

We have optimized chemotherapy. We have sequenced chemotherapy. We have celebrated modest gains.

But the central driver of PDAC has always been sitting there in plain sight:

RAS.

More than 90% of pancreatic cancers have oncogenic RAS mutations, and until recently, we had essentially nothing direct to do about it.

Daraxonrasib is an oral RAS(ON) multiselective inhibitor targeting the active GTP-bound state of mutant and wild-type RAS.

And in RASolute 302, it delivered.

Quick hits:

📌 Phase 3 international randomized trial 500 patients with previously treated mPDAC Daraxonrasib vs investigator’s choice chemotherapy

🧬 RAS G12 population
91.8% of patients had RAS G12 mutations

📈 OS in RAS G12 population
13.2 vs 6.6 months
HR 0.40
P<0.001

📈 OS in overall population
13.2 vs 6.7 months
HR 0.40
P<0.001

📊 PFS in RAS G12 population
7.3 vs 3.5 months
HR 0.45
P<0.001

📊 PFS in overall population
7.2 vs 3.6 months
HR 0.49
P<0.001

🔥 12-month OS
Overall population: 53.2% vs 17.3%

⚠️ Toxicity matters, but this was not just more efficacy for more toxicity
Grade ≥3 AEs: 61.8% vs 69.6%
TRAEs leading to discontinuation: 1.2% vs 11.2%

This is the kind of survival curve we almost never get to see in pancreatic cancer.

This validates RAS(ON) inhibition in the most RAS-addicted major cancer. It takes a target we have talked about for decades and turns it into a clinically meaningful survival benefit in a randomized phase 3 trial.

The next questions come fast: 1L combinations, maintenance, perioperative disease, sequencing, resistance, toxicity management, and whether this becomes a new backbone.

RAS is here, and it couldn’t have come sooner.

https://t.co/Y4WJRlRRTk

@TheGutonclab @UGrewalMD @TimothyJBrownMD @OncoAlert @Onco_Nexus @ASCO
@NazliDizman @LauraAlderMD @DVAraujoMD @DrBarbiOnc @LauraEsfeller @FunchainMD @YGaritaonaindia @DrSAHaddad @jgong15 @iandresmeraz @SakditadMD @RamilaShilpakar @RohitBanwar @lungoncdoc

[OncoAlert @OncoAlert]

Dear Colleagues at #ASCO26 , Welcome to Chicago!
OncoAlert is proud to be covering another great ASCO meeting and we invite you to follow OncoAlert more up to the minute congress coverage.
As Always, Great Content, By Colleagues...For Colleagues

@DrChoueiri 🇺🇸
@hoperugo 🇺🇸
@matteolambe 🇮🇹
@TiansterZhang 🇺🇸
@CathyEngMD 🇺🇸
@stolaney1 🇺🇸
@montypal 🇺🇸
@tompowles1 🇬🇧
@brian_rini 🇺🇸
@cdanicas 🇪🇸
@NiuSanford 🇺🇸
@amerseburger 🇩🇪
@GlopesMd 🇺🇸
@Icro_Meattini 🇮🇹
@PGrivasMDPhD 🇺🇸
@DrYukselUrun 🇹🇷
@nataliagandur 🇦🇷
@ElisaAgostinett 🇧🇪
@HHorinouchi 🇯🇵
@realbowtiedoc 🇺🇸
@to_be_elizabeth 🇮🇹
@UOzkerim 🇹🇷
@p_ciracimd 🇮🇹
@DrVilmaPBarcia 🇪🇸
@DraMartinezLago 🇪🇸
@DrMirallas 🇺🇸
@GaiaGriguolo 🇮🇹
@MarioBalsaMD 🇪🇸
@scocmem 🇬🇧
@AmandaNizamMD 🇺🇸
& @weoncologists 🇺🇸

[Bartomeu Massuti @bmassuti2]

ROSETA Trial of Pumitamig a bi-especific PD-L1 and VEGF-A MoAb: active in both hiistokogies and independently of PD-L1 expression @OncoAlert

[Bartomeu Massuti @bmassuti2]

HLX43 activity in pretreated NSCLC even in EGFR mut+ and PD-L1 negative patients #ASCO26 @OncoAlert

[Mario Balsa @MarioBalsaMD]

🫁 D3S-001: first-line elisrasib ± pembrolizumab in KRAS G12C-mutant NSCLC #ASCO26

🎯 Elisrasib monotherapy: ORR 78.0%, mPFS 12.4 months, 12-month OS 90%
💥 Elisrasib + pembrolizumab: ORR 81.3%, mPFS not reached, 12-month OS 88.8%
⚡ Responses were rapid, with most responders achieving response by week 6
🚨 Higher grade ≥3 TRAEs with the combination (32.7%)

The response rates are elis-rising…now we wait to see whether phase III data can truly KRAS the finish line 😉 #ASCO26

@OncoAlert @OncoReporte
@ASCO @_SEOM @LungCancerRx @Lung_Cancers